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Background and purpose Whether pharmacologically altered high-density lipoprotein cholesterol 
(HDL-C) affects the risk of cardiovascular events is unknown. Recently, we have reported the 
Prevention of Cardiovascular Events in Asian Patients with Ischaemic Stroke at High Risk of 
Cerebral Haemorrhage (PICASSO) trial that demonstrated the non-inferiority of cilostazol to aspirin 
and superiority of probucol to non-probucol for cardiovascular prevention in ischemic stroke 
patients (clinicaltrials.gov: NCT01013532). We aimed to determine whether on-treatment HDL-C 
changes by cilostazol and probucol influence the treatment effect of each study medication during 
the PICASSO study.
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Introduction
High-density lipoprotein cholesterol (HDL-C) has shown an in-
verse association between its level and the risk of cardiovascular 
disease in observational studies.1-3 This association has also been 
persistent in most post hoc analyses and meta-analyses of statin 
trials.4-8 HDLs contribute to the process of cellular cholesterol ef-
flux; therefore, pharmacological elevation of HDL-C levels may 
improve cardiovascular outcomes. However, recent clinical trials 
testing the efficacy of cholesteryl ester transfer protein (CETP) 
inhibitors that increase HDL-C levels have failed to demonstrate 
definite clinical benefits9-11 due to a lack of significant associa-
tion between HDL-C levels per se and cardiovascular risk; how-
ever, the intrinsic nature of CETP inhibitors (e.g., increasing ath-
erogenic apoproteins) may also have affected the results.12 Phar-
macologically altered HDL-C levels having different mechanisms 
may give rise to different results.
HDL-C can be altered by medications other than CETP inhibi-
tors during secondary cardiovascular prevention. For instance, 
cilostazol has been reported to increase HDL-C levels by acti-
vating lipoprotein lipase.13-16 Meanwhile, probucol upregulates 
CETP that significantly decreases HDL-C levels,17 which has 
been considered a deleterious side effect, preventing the wide-
spread use of probucol.17,18
In this study, we hypothesized that medications altering 
HDL-C levels may influence cardiovascular risks. To test this 
hypothesis, we used the recent published data of the Preven-
tion of Cardiovascular Events in Asian Patients with Ischaemic 
Stroke at High Risk of Cerebral Haemorrhage (PICASSO) study.19 
In the study, cilostazol was non-inferior to aspirin for the pre-
vention of cardiovascular events, while the addition of probu-
col to aspirin or cilostazol was superior to non-probucol treat-
ment. Notably, the opposite study medications (cilostazol and 
probucol) in terms of HDL-C alteration were administered in 
the study. Here, we aimed to determine whether on-treatment 
changes in HDL-C levels induced by cilostazol and probucol 
would influence the treatment effect of each study medication.
Methods
Study design and population
The PICASSO trial had a factorial design consisting of two main 
study arms—antiplatelet regimens (cilostazol vs. aspirin) and 
lipid-lowering regimens (standard statin-based therapy plus 
probucol vs. standard statin-based therapy only). The rationale, 
design, and relevant information of the study have been previ-
ously described.19,20
Briefly, we included patients who (1) had a history of a non-
cardioembolic ischemic stroke or transient ischemic attack with-
in 180 days prior to enrollment; (2) were older than 20 years; 
and (3) had a history of either a previous intracerebral hemor-
rhage (ICH) based on clinical history or radiologic findings (over 
8 mm in size on gradient echo imaging) or multiple (two or 
more) cerebral microbleeds on gradient echo imaging. We ex-
cluded patients who (1) had a history of a hemorrhagic stroke 
within the past 6 months; (2) had conditions contraindicating 
long-term antiplatelet therapy; and (3) required dual antiplatelet 
therapy for a recent acute coronary syndrome or a percutaneous 
coronary intervention. Participants who met the criteria were 
consecutively recruited by local investigators. All participants or 
Methods Of the 1,534 randomized patients, 1,373 (89.5%) with baseline cholesterol parameters were 
analyzed. Efficacy endpoint was the composite of stroke, myocardial infarction, and cardiovascular 
death. Cox proportional hazards regression analysis examined an interaction between the treatment 
effect and changes in HDL-C levels from randomization to 1 month for each study arm.
Results One-month post-randomization mean HDL-C level was significantly higher in the cilostazol 
group than in the aspirin group (1.08 mmol/L vs. 1.00 mmol/L, P<0.001). The mean HDL-C level was 
significantly lower in the probucol group than in the non-probucol group (0.86 mmol/L vs. 1.22 
mmol/L, P<0.001). These trends persisted throughout the study. In both study arms, no significant 
interaction was observed between HDL-C changes and the assigned treatment regarding the risk of 
the efficacy endpoint.
Conclusions Despite significant HDL-C changes, the effects of cilostazol and probucol treatment 
on the risk of cardiovascular events were insignificant. Pharmacologically altered HDL-C levels may 
not be reliable prognostic markers for cardiovascular risk.
Keywords Cholesterol, HDL; Secondary prevention; Cilostazol; Probucol; Cholesterol ester transfer 
proteins
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their legally authorized representatives provided informed con-
sent prior to study enrollment.
Between August 2009 and August 2015, 1,568 patients who 
recovered from stroke from 67 centers were initially screened 
in three countries (South Korea, China [Hong Kong], and Philip-
pines), and 1,534 were enrolled in the study (Figure 1). Patients 
were randomly assigned (1:1:1:1) to receive oral cilostazol (100 
mg twice a day), aspirin (100 mg once a day), cilostazol plus 
probucol (250 mg twice a day), or aspirin plus probucol. Adher-
ence to statin therapy as outlined in clinical practice guidelines 
was strongly recommended. The antiplatelet arm was a double-
blind, double-dummy, placebo-controlled, randomized trial, 
while the probucol arm was an open-labeled, blind endpoint 
evaluation trial. The outcome assessor was blinded to the par-
ticipants’ treatment assignment.
The trial protocol was conducted in accordance with the 
Good Clinical Practice Guidelines and the Declaration of Hel-
sinki and was approved by the respective ethics committees 
and Institutional Review Boards of all participating local cen-
ters. This study was registered at the ClinicalTrials.gov 
(NCT01013532).
Follow-up and outcomes
Patients’ follow-up visits took place at 1, 4, 7, 10, and 13 
months after randomization; thereafter, patients visited the 
centers annually. Lipid levels (low-density lipoprotein choles-
terol [LDL-C], HDL-C, and triglycerides) were assessed at base-
line (i.e., at randomization), at 1-month follow-up visit, and 
annually thereafter. Blood test for cholesterol profile was rec-
ommended in all patients; however, patients who refused to 
undergo the test were still included in the PICASSO trial.
The primary efficacy endpoint was a composite of stroke, 
myocardial infarction, and cardiovascular death. The primary 
safety endpoint was hemorrhagic stroke, including spontane-
ous ICH and subarachnoid hemorrhage. All reported endpoints 
of interest were blindly judged by the Central Independent Ad-
judication Committee at the regular meeting.
Statistical analysis
Patients’ baseline characteristics were compared between the 
treatment groups with Pearson’s chi-square tests or Fisher’s ex-
act test for categorical variables and t-test or Wilcoxon rank-
sum test for continuous variables, as appropriate. Longitudinal 
changes in cholesterol levels (LDL-C, HDL-C, and triglycerides) 
were compared between the study groups using the generalized 
estimating equations method. To examine whether the non-in-
feriority of cilostazol to aspirin and superiority of probucol to 
non-probucol were evident in our study population as in the 
previous study,19 we first tested the efficacy of the study medi-
cations to prevent the composite primary efficacy endpoint; 
non-inferiority was observed if the upper limit of the 95% con-
fidence intervals (CIs) of the hazard ratio (HR) did not exceed 
1.25. Additionally, Cox proportional hazards models were used 
to calculate HRs for the outcome variables.
We evaluated whether the treatment effect of the study med-
ication was influenced by HDL-C alterations during the study. 
Poisson regression was performed according to HDL-C changes 
from baseline to on-treatment levels measured 1 month after 
Figure 1. Trial profile. Among the intention-to-treat (ITT) population including all randomized patients in the Prevention of Cardiovascular Events in Asian 
Patients with Ischaemic Stroke at High Risk of Cerebral Haemorrhage study, those who underwent baseline cholesterol evaluation were analyzed in this study.
34 Excluded
 26  No previous intracerebral hemorrhage or cerebral microbleeds
 2  Recent myocardial infarction
 2  Bleeding diathesis
 4  Congestive heart failure
1,568 Screened for eligibility




40 Did not undergo
baseline cholesterol test
42 Did not undergo
baseline cholesterol test
43 Did not undergo
baseline cholesterol test



















Vol. 22 / No. 1 / January 2020
https://doi.org/10.5853/jos.2019.02551 http://j-stroke.org 111
randomization; quartile categories for HDL-C changes were sep-
arately obtained for each treatment arm. In this analysis, the 
outcome variables 1 month after randomization were evaluated. 
Considering that there was no outcome event that had devel-
oped during this initial 1-month period, any patient with early 
outcomes in this post hoc analysis was not excluded. A complete 
case analysis was performed using only cases with no missing 
values. The annualized event rates (%) and 95% CIs in the quar-
tile groups were estimated and compared. Finally, Cox propor-
tional hazards regression analysis was performed to examine an 
interaction effect between the treatment group and changes in 
HDL-C levels for 1 month. To compare the treatment groups, we 
used a two-sided significance level of 0.05. All statistical analy-
ses were performed using the Statistical Analysis System (SAS) 
version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Of the 1,534 patients randomized in the PICASSO trial, 1,373 
(89.5%) with baseline cholesterol parameters were analyzed in 
this study (Figure 1). The median age was 66.1±10.8 years, and 
a total of 530 participants (38.6%) were female. The median 
duration of follow-up was 1.9 years (interquartile range, 1.0 to 
3.0). Considering the 2×2 factorial design of the PICASSO trial, 
the interaction between antiplatelet therapy and probucol 
therapy was assessed before the effect of each treatment arm 
was evaluated. Significant interactions were not observed;19 
thus, the effects on outcomes of antiplatelet drugs and probu-
col were separately analyzed. Study groups’ demographic and 
clinical characteristics were well balanced (Table 1). Statin 
treatment was initiated in 1,080 patients (78.7%) at baseline.
The cholesterol profiles over time are shown in Figure 2. In the 
antiplatelet study arm, cilostazol users showed significantly 
higher HDL-C levels than aspirin users at 1 month (mean HDL-C, 
cilostazol vs. aspirin, 41.8 mg/dL [1.08 mmol/L] vs. 38.8 mg/dL 
[1.00 mmol/L]). This trend persisted throughout the study (Figure 
2A). Additionally, triglyceride levels were significantly lower at 1 
month with cilostazol treatment than with aspirin treatment 
(mean triglyceride, cilostazol vs. aspirin, 100.8 mg/dL [1.14 
mmol/L] vs. 124.9 mg/dL [1.41 mmol/L]), and this trend was also 
maintained thereafter (Figure 2B). Regarding LDL-C, both treat-
ment groups showed comparable levels during the study, except 
at 13 months after treatment (Figure 2C).
In the probucol study arm, HDL-C levels significantly de-
creased in the probucol group but increased in the non-probu-
col group 1 month after randomization. The difference between 
the treatment groups was significant (mean HDL-C at 1 month, 
probucol vs. non-probucol, 33.4 mg/dL [0.86 mmol/L] vs. 47.3 
mg/dL [1.22 mmol/L]) (Figure 2D). Triglyceride levels were also 
affected by probucol treatment at 1 and 13 months after 
treatment, but the difference was not as significant as in the 
antiplatelet study arm (Figure 2E). LDL-C levels were signifi-
cantly lower in the probucol group than in the non-probucol 
group 1 month after randomization (mean LDL-C at 1 month, 
probucol vs. non-probucol, 74.2 mg/dL [1.92 mmol/L] vs. 78.4 
mg/dL [2.23 mmol/dL]) (Figure 2F).
Outcome analyses are shown in Table 2. Consistent with the 
intention-to-treat analysis,19 cilostazol treatment was non-in-
ferior to aspirin (P=0.006) but not superior to aspirin in a supe-
riority test (P=0.137) in the prevention of the primary efficacy 
outcomes. The safety outcome, hemorrhagic stroke, tended to 
occur less frequently in the cilostazol group than in the other 
groups, but this difference was statistically insignificant. In the 
probucol arm, addition of probucol to cilostazol or aspirin was 
non-inferior (P=0.001) and superior (P=0.033) to cilostazol or 
aspirin alone. Probucol treatment did not increase the risk of 
the safety outcome.
Subsequently, we analyzed whether increased and decreased 
HDL-C levels altered the annualized event rates of the primary 
efficacy endpoint in the study medication groups (Figure 3). At 1 
month after randomization, the distribution of HDL-C levels had 
shifted rightward as a result of cilostazol treatment, while it had 
shifted leftward with probucol treatment. The annualized risk of 
the endpoints 1 month after randomization was evaluated ac-
cording to quartiles of change in HDL-C levels from baseline to 1 
month. As a result, there was no significant main effect of the 
change in HDL-C levels regarding the risk of the primary end-
point within each treatment group (P=0.508 in the cilostazol 
group, P=0.894 in the aspirin group, P=0.841 in the probucol 
group, P=0.779 in the non-probucol group). Moreover, there was 
also no significant interaction between treatment group alloca-
tion and HDL-C changes in terms of the risk of the primary effi-
cacy endpoint (P=0.623 in the antiplatelet arm, P=0.997 in the 
probucol arm) (Table 3). Notably, the annualized event rate of 
the primary efficacy endpoint in the probucol group was consis-
tently lower than that in the non-probucol group throughout all 
quartiles of HDL-C changes (Figure 3C).
Finally, we performed Cox proportional hazards regression 
analysis to evaluate an interaction effect between the treat-
ment effects of each medication (cilostazol vs. aspirin; probu-
col vs. non-probucol) and numerical changes in HDL-C levels 
from baseline to 1 month. No significant interactions between 
the treatment effect (HRs for the efficacy endpoint) and HDL-C 
alterations were observed in both study arms (P=0.158 for ci-
lostazol in the antiplatelet arm, P=0.532 for probucol in the 
probucol arm) (Figure 4).
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Table 1. Baseline characteristics
Characteristic










Age (yr) 65.9±10.8  66.2±10.7 0.601 65.8±10.8 66.3±10.7 0.379
Male sex 421 (62) 422 (61) 0.855 417 (61) 426 (62) 0.642
Body mass index (kg/m2) 24.4±3.5 24.3±3.5 0.479 24.5±3.5 24.2±3.5  0.087
Entry event 0.638 0.126
Ischemic stroke 653 (96) 656 (95) 660 (96) 649 (94)
Transient ischemic attack 30 (4) 34 (5) 26 (4) 38 (6)
Index of high risk of ICH 0.907 0.791
Prior history of ICH 140 (20) 144 (21) 137 (20) 147 (21)
Imaging findings of ICH without clinical 
history
129 (19) 124 (18) 129 (19) 124 (18)
Multiple microbleeds 414 (61) 422 (61) 420 (61) 416 (61)
Time-to-randomization since entry event 
(day)
18 (8–40) 17 (8–36) 0.615 18 (8–38) 17 (8–38) 0.417
Risk factors 
Hypertension 603 (88) 614 (89) 0.683 614 (90) 603 (88) 0.312
Diabetes 214 (31) 226 (33) 0.573 211 (31) 229 (33) 0.307
Current smoking 135 (20) 149 (22) 0.403 144 (21) 140 (20) 0.779
Lipids (mg/dL)*
HDL-C 45.1±11.8 45.3±12.2 0.847 45.3±12.1 45.1±11.9 0.689
LDL-C 102.3±36.7 102.9±34.8 0.748 104.5±35.8 100.7±35.6 0.047
Triglycerides 125.3±89.4 132.6±83.2 0.116 131.9±93.6 126.1±78.6 0.218
Fazekas score† 0.505 0.440
0 0 (0) 2 (0) 1 (0) 1 (0)
1 184 (28) 203 (30) 186 (28) 201 (31)
2 296 (45) 290 (43) 309 (46) 277 (42)
3 174 (27) 176 (26) 171 (26) 179 (27)
Intima-media thickness 1.11±0.13 1.10±0.13 0.229 1.11±0.13 1.10±0.13 0.113
Ankle-brachial index 0.91±0.25 0.93±0.24 0.353 0.92±0.25 0.92±0.24 0.897
Concomitant therapy 0.608
Statin 535 (78) 545 (79) 0.767 539 (79) 541 (79) 0.936
Low intensity 8 (2) 9 (2)
0.848
8 (2) 9 (2)
0.655Moderate intensity 313 (61) 309 (59) 317 (62) 305 (59)
High intensity 191 (37) 202 (39) 189 (37) 204 (39)
ARB/ACEI 414 (61) 372 (54) 0.012 391 (57) 395 (57) 0.852
Dihydropyridine 323 (47) 315 (46) 0.543 315 (46) 323 (47) 0.683
Beta blockers 72 (11) 70 (10) 0.809 77 (11) 65 (9) 0.283
Thiazide 98 (14) 86 (12) 0.305 97 (14) 87 (13) 0.422
Values are presented as mean±standard deviation, number (%), or median (interquartile range). 
ICH, intracerebral hemorrhage; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ARB, angiotensin II receptor blocker; 
ACEI, angiotensin-converting enzyme inhibitor.
*To convert cholesterol and triglyceride values to millimoles per liter, multiply by 0.02586 and 0.01129, respectively; †Data evaluated for patients who 
underwent magnetic resonance imaging with fluid-attenuated inversion recovery sequences. 
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Figure 2. Cholesterol profiles over time. (A) High-density lipoprotein cholesterol (HDL-C), (B) triglyceride, and (C) low-density lipoprotein cholesterol (LDL-C) 
levels in the antiplatelet study arm, (D) HDL-C, (E) triglyceride, and (F) LDL-C levels in the probucol study arm. The P-values using the generalized estimated 
equations for probucol-by-visit interaction: cilostazol vs. aspirin, HDL-C (P<0.001), triglycerides (P=0.004), LDL-C (P=0.007); probucol vs. non-probucol, HDL-C 
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Table 2. Primary outcome measures in this study population
Variable









HR (95% CI) P
Efficacy endpoint*




No. of events 55 73 53 75
Rate (%/patient-year) 4.06 (3.11–5.28) 5.27 (4.19–6.62) 3.76 (2.87–4.92) 5.63 (4.49–7.07)
Safety endpoint§
Hemorrhagic stroke 0.42 (0.17–1.02) 0.054 0.68 (0.30–1.54) 0.359
No. of events 7 17 10 14
Rate (%/patient-year) 0.52 (0.25–1.08) 1.22 (0.76–1.97) 0.71 (0.38–1.32) 1.05 (0.62–1.77)
HR, hazard ratio; CI, confidence interval.
*Efficacy endpoint: a composite of stroke, myocardial infarction, and cardiovascular death; †P-value for non-inferiority test with a non-inferiority margin of 
1.25; ‡P-value for superiority test; §Safety endpoint: hemorrhagic stroke.
Figure 3. The annualized risk of the primary endpoint beginning at 1 month, according to quartiles of change in high-density lipoprotein cholesterol (HDL-C) 
levels from baseline to 1 month after randomization. (A) Efficacy endpoint (a composite of stroke, myocardial infarction, and cardiovascular death), (B) safety 
endpoint (cerebral hemorrhage) in the antiplatelet study arm, (C) efficacy endpoint, and (D) safety endpoint in the probucol study arm. The position of each 
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Discussion
We investigated whether the efficacy of study medications was 
altered with on-treatment HDL-C changes in patients with an 
ischemic stroke at high risk of cerebral hemorrhage. Cilostazol 
and probucol treatment demonstrated opposite effects on 
HDL-C levels during the study; however, both changes were in-
significant. These findings suggest that pharmacologically al-
tered HDL-C levels and their changes during active prevention 
may not be reliable prognostic markers to estimate the risks of 
cardiovascular events.
Regarding cholesterol profiles, patients who received cilostazol 
showed higher HDL-C levels and lower triglyceride levels than 
those who received aspirin. These changes are consistent with 
that of the previous reports13-16 and may be attributable to in-
creased lipoprotein lipase activity.14 In the probucol study arm, 
both HDL-C and LDL-C levels were remarkably lower in the pro-
bucol group than in the non-probucol group, while triglycerides 
were relatively comparable between the treatment groups. These 
profiles were also consistent with the previous study findings.21-23 
The upregulation of CETP by probucol was associated with in-
creased HDL-C levels.17
Table 3. Annual event rate according to quartiles of high-density lipoprotein cholesterol 1 month after randomization
Variable
Antiplatelet arm  Probucol arm
Cilostazol Aspirin P * P † Probucol Non-probucol P * P †
Efficacy endpoint‡ 0.623 0.997 
1st quartile 2.40 (1.20–4.79) 4.77 (2.92–7.79) 0.112 3.69 (2.09–6.50) 6.25 (4.03–9.69) 0.149 
2nd quartile 3.44 (1.90–6.21) 4.33 (2.56–7.31) 0.568 2.70 (1.40–5.18) 5.09 (3.16–8.18) 0.123 
3rd quartile 3.90 (2.27–6.72) 3.79 (2.24–6.39) 0.937 2.68 (1.39–5.15) 4.51 (2.72–7.47) 0.217 
4th quartile 4.61 (2.78–7.64) 4.93 (2.97–8.18) 0.852 2.70 (1.45–5.02) 4.79 (2.84–8.08) 0.166 
Safety endpoint§ 0.864 0.655 
1st quartile 0.60 (0.15–2.40) 0.60 (0.15–2.38) 0.996 0.92 (0.30–2.86) 0.94 (0.30–2.91) 0.984 
2nd quartile 0.31 (0.04–2.22) 0.62 (0.15–2.47) 0.578 0.30 (0.04–2.13) 1.49 (0.62–3.59) 0.142 
3rd quartile 0.60 (0.15–2.40) 1.62 (0.73–3.61) 0.224 0.60 (0.15–2.38) 0.60 (0.15–2.40) 0.994 
4th quartile 0.61 (0.15–2.45) 1.64 (0.68–3.95) 0.239 0.81 (0.26–2.51) 1.03 (0.33–3.18) 0.772 
Values are presented as annualized event rate (%) and 95% confidence interval.
*P-value by Poisson regression for treatment-by-quartile interaction; †P-value by contrast test with Poisson regression for each quartile; ‡Efficacy endpoint: a 





































Change in HDL-C (mg/dL) from baseline to month 1
P for interaction=0.532
Cilostazol (vs. aspirin) Probucol (vs. non-probucol)
Figure 4. Hazard ratio for the composite vascular event of the study medication group vs. the control group according to numerical changes in high-density 
lipoprotein cholesterol (HDL-C) levels from baseline to 1-month post-randomization. (A) Cilostazol vs. aspirin, (B) probucol vs. non-probucol. No significant in-
teractions between the treatment effect and HDL-C alterations were observed in both study arms (Cox proportional hazards regression analysis, P=0.158 for 
cilostazol in the antiplatelet arm, P=0.532 for probucol in the probucol arm). CI, confidence interval.
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Regarding the outcome analyses, non-inferiority of cilostazol 
to aspirin treatment in reducing composite vascular outcomes 
was evident in our population. Importantly, the post hoc analyses 
of endpoints did not show any significant interaction between 
the cilostazol effect and HDL-C changes (Figures 3 and 4), sug-
gesting that increased HDL-C levels may not enhance the drug 
efficacy in secondary prevention. Meanwhile, probucol treatment 
was superior to non-probucol treatment in preventing the pri-
mary efficacy endpoint in this study population. The treatment 
effects of probucol were also comparable, regardless of HDL-C 
changes (Figures 3 and 4), suggesting that the clinical benefits 
of the drug may not be affected by a decrease in HDL-C levels. 
Meta-analyses performed in 17 genetic studies revealed that a 
causal role for HDL-C on the risk of coronary heart disease is not 
evident.24 Additionally, genetic mechanisms that increase HDL-C 
levels did not lower the risk of myocardial infarction.25 Accord-
ingly, recent large clinical trials assessing the efficacy of the CETP 
inhibitors have not demonstrated definite clinical benefits in pa-
tients with high cardiovascular risk. Despite increases in HDL-C 
levels by greater than 70% to 100%, torcetrapib and dalcetrapib 
failed to prove their efficacy in secondary prevention.9,10 Anace-
trapib showed a modest benefit by reducing major coronary 
events;11 however, its effect could not be attributed solely to the 
fact that it increased HDL-C-levels because it also significantly 
lowered LDL-C levels.12
The following are the several potential explanations regard-
ing the lack of association between HDL-C levels and clinical 
benefits:10,26 (1) HDL-C level may lose its role as a determinant 
of cardiovascular risk when patients are treated with evidence-
based therapy in a clinical trial setting; (2) the protective effect 
of HDL-C may be limited to healthy individuals, not patients 
who already have cardiovascular disease; (3) the measured 
HDL-C levels may not fully reflect the physiologic functions of 
HDLs; and (4) cholesterol efflux capacity rather than HDL-C 
level per se is the crucial determinant of cardiovascular risk.26 
Therefore, probucol’s HDL-C-lowering effect does not neces-
sarily have to be considered a significant adverse effect.
What is the mechanism for beneficial effects of probucol? A 
greater reduction in LDL-C in probucol users may not explain the 
clinical benefit of probucol because the degree of difference be-
tween the treatment groups was less than 5 mg/dL (0.1 mmol/L) 
throughout the study. Considering that a 20% reduction in the 
risk of cardiovascular disease is achieved by each reduction of 40 
mg/dL (1 mmol/L) in the LDL-C level,5 a 31% reduction in the in-
cidence of the primary endpoint in our study may have come 
from a decrease in the residual cardiovascular risk rather than 
from LDL-C lowering activity. The upregulation of CETP may have 
converted the whole HDL-C into smaller particles that are more 
effectively excreted,27 decreasing the body’s total cholesterol bur-
den. Additionally, other known pleiotropic effects of the drug 
may have induced the observed clinical benefits.17,18,28-30 Particu-
larly, endothelial dysfunction and increased vascular permeability 
are associated with ischemic and hemorrhagic strokes.31 These 
strokes are the clinical characteristics of our participants, and 
probucol may have had beneficial effects in both of these factors.
This study has several limitations. First is the study’s post hoc 
design, which is prone to be affected by chance and confounding 
biases. Second, the number of study participants was not deter-
mined to examine the prognostic value of HDL-C levels; hence, 
the study may not have sufficient power to verify the effect of 
on-treatment HDL-C changes on the risk of cardiovascular 
events. Therefore, the results of this study should be cautiously 
interpreted and regarded as an observational evidence. Third, 
cholesterol profiles are not available in all patients. Despite a pro-
file that is evident, particularly for HDL-C levels, the results of this 
profile should be cautiously interpreted. Fourth, the degree of 
HDL-C increases by cilostazol may be significantly small to mani-
fest its effect in enhancing the treatment efficacy of the study 
medication. Previous trials to test CETP inhibitors have resulted in 
a greater difference on HDL-C levels between the treatment 
groups (e.g., mean HDL-C level during the study: dalcetrapib vs. 
placebo, 55 mg/dL [1.42 mmol/L] vs. 43 mg/dL [1.11 mmol/L] at 1 
month; anacetrapib vs. placebo, 85 mg/dL [2.20 mmol/L] vs. 42 
mg/dL [1.09 mmol/L] at midpoint).10,11 However, it should also be 
noted that these CETP inhibitors have demonstrated only modest 
or no clinical benefits. Fifth, we did not consider the subtypes of 
stroke in our analyses, such as Trial of Org 10172 in Acute Stroke 
Treatment classification, because information about cerebral ves-
sels has not been obtained. This point should be considered be-
cause the detrimental effect of HDL-C reduction may be less no-
ticeable in patients with small-vessel occlusion. This occlusion 
may be a more common stroke subtype in our participants com-
pared to individuals with large artery atherosclerosis. Finally, be-
cause only Asian patients are enrolled in this study, the results 
may not be generalizable to other ethnicities.
Conclusions
It is evident that cilostazol and probucol treatment caused sig-
nificant HDL-C changes during the PICASSO study. Notably, 
cardiovascular risks and their treatment efficacy were not in-
fluenced by on-treatment HDL-C changes. These findings sug-
gest that pharmacologically altered HDL-C levels may not be 
reliable prognostic markers for cardiovascular risk, reaffirming 
the recent failures of CETP inhibitor trials.
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